Search Results

FDA proposes expanding antidepressant warning to young adults.

Subjects: *DRUG labeling; *ANTIDEPRESSANTS; *PHARMACEUTICAL industryUNITED StatesUNITED States. Food & Drug Administration

• Source: Mental Health Weekly. 5/7/2007, Vol. 17 Issue 18, p5-6. 2p.

Record details

Advocates pleased with FDA review of ADHD medications.

Subjects: *DRUG labeling; *ATTENTION-deficit hyperactivity disorder; *PHARMACODYNAMICSUNITED StatesUNITED States. Food & Drug Administration

• Source: Mental Health Weekly. 4/3/2006, Vol. 16 Issue 14, p4-5. 2p.

Record details

Study examines psychosis risk with amphetamine prescriptions.

• Authors : Canady, Valerie A.

Subjects: RISK assessment; AMPHETAMINES; AGE distribution

• Source: Mental Health Weekly. 9/16/2024, Vol. 34 Issue 35, p4-5. 2p.

Record details

FDA approves first generic Abilify to treat mental illnesses.

• Authors : Canady, Valerie A.

Subjects: ANTIDEPRESSANTS; MENTAL depression; DRUG therapy for schizophrenia

• Source: Mental Health Weekly. May2015, Vol. 25 Issue 18, p6-7. 2p.

Record details

FDA approves new treatment for Alzheimer's disease.

• Authors : Canady, Valerie A.

Subjects: THERAPEUTIC use of monoclonal antibodies; DRUG approval; DRUG efficacyUNITED States

• Source: Mental Health Weekly. Jan2023, Vol. 33 Issue 3, p6-7. 2p.

Record details

FDA approves real-world data for inclusion in label update.

• Authors : Canady, Valerie A. (AUTHOR)

Subjects: DRUG therapy for schizophrenia; ARIPIPRAZOLE; ANTIPSYCHOTIC agents

• Source: Mental Health Weekly. 1/8/2018, Vol. 28 Issue 2, p7-8. 2p.

Record details

Drug manufacturer to pay $31 million in Medicaid settlement.

Subjects: ECONOMIC impact; MEDICAID; MEDICAL economicsNEW York (State)

• Source: Mental Health Weekly. Oct2014, Vol. 24 Issue 40, p4-5. 2p.

Record details

BRIEFLY NOTED.

Subjects: MENTAL health services; ELI Lilly & Co.; DRUG labelingUNITED States

• Source: Mental Health Weekly. 10/15/2007, Vol. 17 Issue 39, p7-7. 1/2p.

Record details

FDA committee recommends black box warning for ADHD drugs.

Subjects: ATTENTION-deficit hyperactivity disorder; PHARMACEUTICAL policy; DRUG monitoringUNITED StatesUNITED States. Food & Drug Administration

• Source: Mental Health Weekly; 3/20/2006, Vol. 16 Issue 12, p4-6, 3p

Record details